Opus Genetics reports FY25 EPS (80c) vs ($2.15) last year

Reports FY25 revenue $14.196M, consensus $13.48M. “We are delivering a steady cadence of data and milestones across our pipeline,” said George Magrath, M.D., Chief Executive Officer, Opus Genetics (IRD). “With positive clinical results from both our BEST1 and LCA5 gene therapy programs, new funding for our MERTK program and an upcoming FDA PDUFA date for Phentolamine Ophthalmic Solution 0.75% in presbyopia, we are advancing therapies with both scientific promise and compelling commercial potential. The reauthorization of the U.S. Rare Pediatric Disease Priority Review Voucher program further strengthens our work, reinforcing long-term incentives that support sustainable investment in rare gene therapy development. With multiple catalysts ahead and a capital-efficient operating model, we believe Opus is positioned to create significant long-term value for shareholders.”